Xcout IntelBioSplice Therapeutics, Inc.
Biosplice Therapeutics, Inc., formerly known as Samumed, LLC, is a private biopharmaceutical company based in San Diego, California. The company focuses on clinical developments such as pivotal trials for knee osteoarthritis.
Subscribe to see BioSplice Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BioSplice Therapeutics, Inc. at a glance
BioSplice Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $340M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round closed in August 2022. Xcout tracks 4 named people at BioSplice Therapeutics, Inc., including Erich Horsley (Chief Executive Officer).
BioSplice Therapeutics, Inc. leadership
- Erich HorsleyChief Executive Officer
- Finian TanFounder and Chairman, Vickers Venture Partners
- Osman KibarFounder and Executive Chairman, Biosplice Therapeutics
- Osman KibarFounder
BioSplice Therapeutics, Inc. funding rounds
At least $340M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | Undisclosed | — | |
| Venture Round | $120M | — | |
| Series A | $220M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
BioSplice Therapeutics, Inc. competitors
A few of BioSplice Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
Kenai Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California. The company pioneers next-generation therapeutic approaches by leveraging induced pluripotent stem cell (iPSC) technology.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
VitaSpring Biomedical Co. Ltd. specializes in pioneering pharmaceutical solutions derived from cellular medicine. It previously operated as Shemn Corp. before rebranding as VitaSpring Biomedical Co. Ltd. in February 2020. The company was established in 2016 and its main operations are based in Irvine, California.
DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Get BioSplice Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BioSplice Therapeutics, Inc. in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access